Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.35 - $1.07 $99,481 - $304,129
284,233 New
284,233 $99,000
Q4 2023

Feb 14, 2024

BUY
$0.56 - $0.8 $1.61 Million - $2.31 Million
2,882,216 New
2,882,216 $1.9 Million
Q4 2020

Feb 16, 2021

BUY
$13.2 - $32.74 $198,000 - $491,100
15,000 New
15,000 $414,000

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.